Latest & greatest articles for acyclovir

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on acyclovir or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on acyclovir and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for acyclovir

1. Acyclovir for Mechanically Ventilated Patients With Herpes Simplex Virus Oropharyngeal Reactivation: A Randomized Clinical Trial

Acyclovir for Mechanically Ventilated Patients With Herpes Simplex Virus Oropharyngeal Reactivation: A Randomized Clinical Trial Acyclovir for Mechanically Ventilated Patients With Herpes Simplex Virus Oropharyngeal Reactivation: A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features (...) a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation JAMA Intern Med Actions 2019 Dec 16 [Online ahead of print] Acyclovir for Mechanically Ventilated Patients With Herpes Simplex Virus Oropharyngeal Reactivation: A Randomized Clinical Trial , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Sorbonne Université

2020 EvidenceUpdates

2. Acyclovir

Acyclovir Top results for acyclovir - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for acyclovir The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted

2018 Trip Latest and Greatest

4. Chickenpox: Aciclovir

Chickenpox: Aciclovir Aciclovir | Prescribing information | Chickenpox | CKS | NICE Search CKS… Menu Aciclovir Chickenpox: Aciclovir Last revised in August 2018 Aciclovir Adverse effects Aciclovir is generally well tolerated. However, it may cause gastrointestinal adverse effects, such as nausea, vomiting, diarrhoea, and abdominal pain. Headache, dizziness, and skin rashes (including photosensitivity and urticaria) have also been commonly reported. [ ; ] Contraindications and cautions Do (...) not prescribe aciclovir to a person with a known allergy to aciclovir or valaciclovir. Prescribe aciclovir with caution in a person who: Is elderly. Has underlying neurological abnormalities. Has severe liver or electrolyte abnormalities. Has significant hypoxia. Has renal impairment — advise the person to maintain adequate hydration. Dose adjustment is required. [ ; ; ] Drug interactions There are no clinically significant drug interactions with aciclovir, although it may increase the plasma concentration

2017 NICE Clinical Knowledge Summaries

5. Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccination Full Text available with Trip Pro

Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccination Varicella zoster virus (VZV) disease (usually cutaneous zoster) occurs frequently after hematopoietic cell transplantation (HCT), and postherpetic neuralgia (PHN) results in poor quality of life. The optimal prophylaxis of VZV disease/PHN has not been established. At our center, before 2008, VZV prophylaxis consisted of ∼1 year of post-HCT acyclovir/valacyclovir ("old (...) strategy"), whereas post-2008 prophylaxis consisted of 2 years of acyclovir/valacyclovir followed by immunization using varicella vaccine ("new strategy"). We performed a retrospective study comparing the cumulative incidence of VZV disease and PHN among patients who completed the old strategy (n = 153) vs the new strategy (n = 125). Patients who completed the old strategy had a significantly higher cumulative incidence of VZV disease (33% vs 17% at 5 years, P ≤ .01) and PHN (8% vs 0% at 5 years, P

2016 Blood advances

6. Valacyclovir versus acyclovir for the treatment of herpes zoster ophthalmicus in immunocompetent patients. Full Text available with Trip Pro

Valacyclovir versus acyclovir for the treatment of herpes zoster ophthalmicus in immunocompetent patients. Herpes zoster ophthalmicus affects the eye and vision, and is caused by the reactivation of the varicella zoster virus in the distribution of the first division of the trigeminal nerve. An aggressive management of acute herpes zoster ophthalmicus with systemic antiviral medication is generally recommended as the standard first-line treatment for herpes zoster ophthalmicus infections. Both (...) acyclovir and its prodrug valacyclovir are medications that are approved for the systemic treatment of herpes zoster. Although it is known that valacyclovir has an improved bioavailability and steadier plasma concentration, it is currently unclear as to whether this leads to better treatment results and less ocular complications.To assess the effects of valacyclovir versus acyclovir for the systemic antiviral treatment of herpes zoster ophthalmicus in immunocompetent patients.We searched CENTRAL (which

2016 Cochrane

7. Acyclovir Prophylaxis Reduces the Incidence of Herpes Zoster Among HIV-Infected Individuals: Results of a Randomized Clinical Trial Full Text available with Trip Pro

Acyclovir Prophylaxis Reduces the Incidence of Herpes Zoster Among HIV-Infected Individuals: Results of a Randomized Clinical Trial Human immunodeficiency virus (HIV)-infected persons have higher rates of herpes zoster than HIV-uninfected individuals. We assessed whether twice daily treatment with 400 mg of oral acyclovir reduces the incidence of herpes zoster in a randomized, double-blind, placebo-controlled trial among 3408 persons coinfected with HIV and herpes simplex virus type 2. During (...) 5175 person-years of follow-up, 26 cases of herpes zoster occurred among those assigned acyclovir, compared with 69 cases among those assigned placebo (rates, 1.00 and 2.68/100 person-years, respectively), a relative decrease of 62% (hazard ratio, 0.38; 95% confidence interval, .24-.67; P < .001). Daily acyclovir prophylaxis significantly reduced herpes zoster incidence among HIV-infected persons. © The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America

2015 EvidenceUpdates Controlled trial quality: predicted high

8. Aciclovir

Aciclovir USE OF ACICLOVIR IN PREGNANCY 0344 892 0909 USE OF ACICLOVIR IN PREGNANCY (Date of issue: August 2018 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Aciclovir is an antiviral agent used systemically for the treatment (...) of herpes simplex and varicella-zoster infections, or topically for herpes simplex infections of the skin, mucous membranes and eye. Valaciclovir, a prodrug of aciclovir, is used systemically in the treatment or prophylaxis of herpes simplex, varicella-zoster and cytomegalovirus infections. Overall, the data do not suggest an increased risk of congenital malformation or other adverse fetal outcomes from exposure to either systemic aciclovir or valaciclovir or topical aciclovir at any time in pregnancy

2014 UK Teratology Information Service

9. Acyclovir versus valacyclovir for herpes virus in children and pregnant women: a review of the clinical evidence and guidelines

Acyclovir versus valacyclovir for herpes virus in children and pregnant women: a review of the clinical evidence and guidelines Acyclovir versus valacyclovir for herpes virus in children and pregnant women: a review of the clinical evidence and guidelines Acyclovir versus valacyclovir for herpes virus in children and pregnant women: a review of the clinical evidence and guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Acyclovir versus valacyclovir for herpes virus in children and pregnant women: a review of the clinical evidence and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions In the last five years there has been very limited new evidence on the effectiveness of oral antivirals in children with chickenpox, pregnant women

2014 Health Technology Assessment (HTA) Database.

10. Idoxuridine 10% Gel Appears Equally Effective As acyclovir 5% Cream In Treating Herpes Labialis

Idoxuridine 10% Gel Appears Equally Effective As acyclovir 5% Cream In Treating Herpes Labialis UTCAT2394, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Idoxuridine 10% Gel Appears Equally Effective As acyclovir 5% Cream In Treating Herpes Labialis Clinical Question Will idoxuridine treatment have a better wound healing outcome than acyclovir in a patient with recurrent Herpes labials? Clinical Bottom Line Acyclovir (...) hours. This is the only study that has been done comparing the two drugs and full article is in French. Evidence Search ("idoxuridine"[Mesh]) AND "Acyclovir"[Mesh]) AND "Herpes labialis"[Mesh} Comments on The Evidence The sole direct comparison study of topical acyclovir against topical idoxuridine in the treatment of herpes labials is only published as a "letter to the editor" in the English language. As such it is not available for review and there is no evidence of study replication. While

2013 UTHSCSA Dental School CAT Library

11. Sitavig (acyclovir ) Buccal Tablet

Sitavig (acyclovir ) Buccal Tablet Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - SITAVIG (acyclovir ) Buccal Tablet Company: BioAlliance Pharma Application No.: 203791 Approval Date: 04/12/2013 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date

2013 FDA - Drug Approval Package

12. Cohort study: Delayed acyclovir therapy in neonates with herpes simplex virus infection is associated with an increased odds of death compared with early therapy

Cohort study: Delayed acyclovir therapy in neonates with herpes simplex virus infection is associated with an increased odds of death compared with early therapy Delayed acyclovir therapy in neonates with herpes simplex virus infection is associated with an increased odds of death compared with early therapy | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time (...) . To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Delayed acyclovir therapy in neonates with herpes simplex virus infection

2013 Evidence-Based Medicine

13. High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial Full Text available with Trip Pro

High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial Standard-dose HSV-2 suppressive therapy (acyclovir 400 mg twice daily) reduces plasma HIV-1 levels by 0.25-0.50 log(10) copies/mL. It is not known if higher doses might further suppress HIV-1 levels.We enrolled 32 HIV-1/HSV-2 dually infected Kenyan individuals who were not on antiretroviral therapy (...) (ART) into a randomized, crossover trial of 2 dosing regimens of HSV-2 suppression: valacyclovir 1.5 g vs acyclovir 400 mg, both twice daily for 12 weeks, then a 2-week washout, and then the alternative for 12 weeks. Weekly plasma HIV-1 RNA quantity was measured (ClinicalTrials.gov number NCT01026454).Mean plasma HIV-1 levels were significantly lower on valacyclovir compared with acyclovir: 2.94 vs 3.56 log(10) copies/mL, an average difference of 0.62 log(10) copies/mL (95% confidence interval [CI

2012 EvidenceUpdates Controlled trial quality: uncertain

14. The cost-effectiveness of herpes simplex virus-2 suppressive therapy with daily aciclovir for delaying HIV disease progression among HIV-1-infected women in South Africa Full Text available with Trip Pro

. Bibliographic details Vickerman P, Devine A, Foss AM, Delany-Moretlwe S, Mayaud P, Meyer-Rath G. The cost-effectiveness of herpes simplex virus-2 suppressive therapy with daily aciclovir for delaying HIV disease progression among HIV-1-infected women in South Africa. Sexually Transmitted Diseases 2011; 38(5): 401-409 PubMedID DOI Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Acyclovir /administration & Adolescent; Antiviral Agents /administration & Cost-Benefit Analysis; Disease (...) The cost-effectiveness of herpes simplex virus-2 suppressive therapy with daily aciclovir for delaying HIV disease progression among HIV-1-infected women in South Africa The cost-effectiveness of herpes simplex virus-2 suppressive therapy with daily aciclovir for delaying HIV disease progression among HIV-1-infected women in South Africa The cost-effectiveness of herpes simplex virus-2 suppressive therapy with daily aciclovir for delaying HIV disease progression among HIV-1-infected women

2011 NHS Economic Evaluation Database.

15. Oral acyclovir suppression and neurodevelopment after neonatal herpes. Full Text available with Trip Pro

Oral acyclovir suppression and neurodevelopment after neonatal herpes. Poor neurodevelopmental outcomes and recurrences of cutaneous lesions remain unacceptably frequent among survivors of neonatal herpes simplex virus (HSV) disease.We enrolled neonates with HSV disease in two parallel, identical, double-blind, placebo-controlled studies. Neonates with central nervous system (CNS) involvement were enrolled in one study, and neonates with skin, eye, and mouth involvement only were enrolled (...) in the other. After completing a regimen of 14 to 21 days of parenteral acyclovir, the infants were randomly assigned to immediate acyclovir suppression (300 mg per square meter of body-surface area per dose orally, three times daily for 6 months) or placebo. Cutaneous recurrences were treated with open-label episodic therapy.A total of 74 neonates were enrolled--45 with CNS involvement and 29 with skin, eye, and mouth disease. The Mental Development Index of the Bayley Scales of Infant Development

2011 NEJM Controlled trial quality: predicted high

16. Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: a randomized, controlled trial Full Text available with Trip Pro

Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: a randomized, controlled trial It is uncertain whether episodic acyclovir will enhance ulcer healing if delivered at primary health care settings, because there is often a delay in treatment initiation.A double-blind, randomized, placebo-controlled trial of 5-day acyclovir (400 mg 3 times daily) was conducted among men with genital ulcers in South Africa. Participants (...) received syndromic management; were tested for ulcer etiology, human immunodeficiency virus (HIV), syphilis, and herpes simplex virus type 2 (HSV-2); and were seen over the course of a month to evaluate ulcer healing and HIV-1 RNA shedding. Outcomes were ulcer duration and HIV-1 RNA shedding, assessed on day 7 among HIV-1-seropositive participants with a herpetic ulcer.A total of 309 men received acyclovir, and 306 received placebo; 63% were HIV-1 positive. There were 295 HIV-1-positive participants

2010 EvidenceUpdates Controlled trial quality: predicted high

17. Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Full Text available with Trip Pro

reduced risk of HIV-1 disease progression by 16%; 284 participants assigned acyclovir versus 324 assigned placebo reached the primary endpoint (hazard ratio [HR] 0.84, 95% CI 0.71-0.98, p=0.03). In those with CD4 counts >or=350 cells per microL, aciclovir delayed risk of CD4 cell counts falling to <350 cells per microL by 19% (0.81, 0.71-0.93, p=0.002)The role of suppression of herpes simplex virus type 2 in reduction of HIV-1 disease progression before initiation of antiretroviral therapy warrants (...) Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Most people infected with HIV-1 are dually infected with herpes simplex virus type 2. Daily suppression of this herpes virus reduces plasma HIV-1 concentrations, but whether it delays HIV-1 disease progression is unknown. We investigated the effect of acyclovir on HIV-1 progression.In a trial with 14 sites in southern Africa and east Africa

2010 Lancet Controlled trial quality: predicted high

18. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. Full Text available with Trip Pro

Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. Most persons who are infected with human immunodeficiency virus type 1 (HIV-1) are also infected with herpes simplex virus type 2 (HSV-2), which is frequently reactivated and is associated with increased plasma and genital levels of HIV-1. Therapy to suppress HSV-2 reduces the frequency of reactivation of HSV-2 as well as HIV-1 levels, suggesting that suppression of HSV-2 may reduce the risk of transmission of HIV-1 (...) .We conducted a randomized, placebo-controlled trial of suppressive therapy for HSV-2 (acyclovir at a dose of 400 mg orally twice daily) in couples in which only one of the partners was seropositive for HIV-1 (CD4 count, > or = 250 cells per cubic millimeter) and that partner was also infected with HSV-2 and was not taking antiretroviral therapy at the time of enrollment. The primary end point was transmission of HIV-1 to the partner who was not initially infected with HIV-1; linkage

2010 NEJM Controlled trial quality: predicted high

19. Treatment with acyclovir five times daily may reduce the duration of primary herpetic oral lesions

Treatment with acyclovir five times daily may reduce the duration of primary herpetic oral lesions UTCAT491, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Treatment with acyclovir five times daily may reduce the duration of primary herpetic oral lesions Clinical Question In children experiencing primary herpetic gingivostomatitis, does treatment with acyclovir, compared to no treatment, reduce the duration of oral (...) lesions? Clinical Bottom Line Treatment with acyclovir 5 times daily could reduce the duration of primary herpetic oral lesions. (See Comments on the CAT below) Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Nasser/2008 Children and young adults Systematic review Key results Two randomized controlled trials were included in this systematic review. One provided weak evidence that acyclovir is an effective

2010 UTHSCSA Dental School CAT Library

20. WITHDRAWN: Aciclovir or valaciclovir for Bell's palsy (idiopathic facial paralysis). (Abstract)

before a definitive recommendation can be made regarding the effect of aciclovir or valaciclovir on Bell's palsy. Two trials, one with 551 participants comparing prednisolone with acyclovir with both and with neither, another with 221 participants comparing prednisolone and valacyclovir with prednisolone and placebo have just been published and will be included in an update of this review. (...) WITHDRAWN: Aciclovir or valaciclovir for Bell's palsy (idiopathic facial paralysis). The most common disorder of the facial nerve is acute idiopathic facial paralysis or Bell's palsy and there may be significant morbidity or incomplete recovery associated with severe cases.To assess the efficacy of aciclovir or similar agents for treating Bell's palsy.We searched the Cochrane Neuromuscular Disease Group register (searched April 2003), MEDLINE (from January 1966 to April 2003), EMBASE (from

2009 Cochrane